Video

Favorable Results for Major Depressive Disorder Patients

Author(s):

Antony Loebel, MD, Executive Vice President and Chief Medical Officer, Sunovion Pharmaceuticals Inc. provided invaluable insight on the first placebo-controlled trial for patients with Major Depressive Disorder with mixed features.

Antony Loebel, MD, Executive Vice President and Chief Medical Officer, Sunovion Pharmaceuticals Inc. provided invaluable insight on the first placebo-controlled trial for patients with Major Depressive Disorder with mixed features.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.